Skip to main content
. Author manuscript; available in PMC: 2012 Jan 1.
Published in final edited form as: J Immunol. 2010 Nov 24;186(1):516–526. doi: 10.4049/jimmunol.1000955

Figure 8. PILR inhibits LTC4 release in response to fMLP stimulation in IL-5/IL-3-primed human blood eosinophils.

Figure 8

Human blood eosinophils were preincubated with 10 μM control peptide or PILR for 30 min. Cells were then primed with control buffer, 100 pM IL-5, or 1 nM IL-3 for 1 hr followed by a 20 min stimulation with 100 nM fMLP. Supernatants were then collected and assayed for immunoreactive LTC4 as described under Materials and Methods. The data are normalized to the LTC4 released from the leftmost bar and presented as fold increases. The dark bars and open bars represent the pretreatment with control peptide and PILR, respectively. Seven independent experiments are summarized and presented as the mean ± (SEM). * p<0.04 **p<0.02, N=7.